Clinuvel Pharmaceuticals Limited (CUVL)
Nasdaq: CUVL · American Depositary Receipts · filing with the SEC since 2004
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in June.| Fiscal year | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Period ending | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 |
| Report filed | Oct 30, 2026 | · | · |
| Revenue | 64,315,354 | 61,120,888 | 57,911,843 |
| Cost of revenue | 10,978,777 | 11,513,474 | 10,741,863 |
| Gross profit | 53,336,577 | 49,607,414 | 47,169,980 |
| Research and development | 12,229,811 | 13,216,521 | 9,994,900 |
| General and administrative | 7,384,954 | 6,677,524 | 6,814,920 |
| Total operating expenses | 25,414,984 | 23,087,357 | 18,641,640 |
| Operating income | 27,921,593 | 26,520,057 | 28,528,340 |
| Interest and investment income | 7,087,314 | 6,119,535 | 4,812,098 |
| Other income (expense), net | 456,914 | -138,096 | 367,521 |
| Income before income taxes | 32,715,335 | 33,092,903 | 33,220,883 |
| Income tax expense | 9,537,501 | 9,970,039 | 9,874,709 |
| Net income | 23,177,834 | 23,122,864 | 23,346,174 |
| Earnings per share, basic | 0.46 | 0.46 | 0.47 |
| Earnings per share, diluted | 0.46 | 0.46 | 0.46 |
| Weighted average shares, basic | 50,009,944 | 50,076,045 | 49,834,035 |
| Weighted average shares, diluted | 50,746,879 | 50,380,016 | 51,026,714 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding